Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

JHL Forms $257 Million Partnership with Sanofi for Rituximab Biosimilar

publication date: Dec 5, 2016
JHL Biotech, a Taiwan-China biologics company, signed a $257 million partnership agreement that gives Sanofi  rights to market a JHL clinical-stage rituximab biosimilar, initially for China. Sanofi also invested $80 million in JHL stock. JHL will develop, register and manufacture the biosimilar, while Sanofi will be in charge of commercialization. Rituximab is used to treat autoimmune disorders, cancer and transplant rejection. JHL received approval to start a European Phase I trial of the rituximab biosimilar in February 2016. More details....

Stock Symbols: (TWO: 6540) (NYSE: SNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital